Advertisement

Im Focus Onkologie

, Volume 21, Issue 9, pp 84–93 | Cite as

Aktuelle Entwicklungen und Ausblick

Medikamentöse Therapie des Nierenzellkarzinoms

  • Jan Roigas
Uroonkologie Zertifizierte Fortbildung
  • 262 Downloads

Zusammenfassung

Das Spektrum der medikamentösen Therapieoptionen beim Nierenzellkarzinom hat sich enorm erweitert. Zugleich ist die Herausforderung größer geworden, zu erkennen, wann welche Therapie eingesetzt werden sollte. Vergessen werden sollte dabei nicht, dass das metastasierte Nierenzellkarzinom selten ist und zunächst palliativ zu behandeln.

Literatur

  1. 1.
    Heng DY et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sternberg CN et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Escudier B et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hudes G et al. ARCC Trial. Temsirolimus, interferon alfa, or both for adanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Motzer RJ et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373(19):1803–13.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Choueiri TK et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814–23.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Motzer RJ et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6): 552–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Motzer RJ et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Motzer RJ et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Escudier B et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 2007;356(2):125–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Choueiri TK et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomized trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–25.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Motzer RJ et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Motzer RJ et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–90.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Motzer R et al. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs. Sunitinib in Untreated Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018; https://doi.org/10.1200/JCO.2018.36.6_suppl.578.CrossRefGoogle Scholar
  16. 16.
    Atkins MB et al. Safety and efficacy of Axitinib (axi) in combination with Pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (arcc). J Clin Oncol. 2018;36(6 Suppl):579–579.CrossRefGoogle Scholar
  17. 17.
    Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    European Association of Urology (EAU) [Internet]. Arnhem/Niederlande: EAU [zitiert am 7.5.2018]. Renal Cell Carcinoma. Verfügbar unter: http://uroweb.org/guideline/renal-cell-carcinoma/.

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Urologie und KinderurologieVivantes Klinikum im FriedrichshainBerlinDeutschland

Personalised recommendations